{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:44:51Z","timestamp":1790934291297,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03404-9","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T07:02:22Z","timestamp":1711004542000},"page":"1779-1789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy"],"prefix":"10.1007","volume":"26","author":[{"given":"Ana","family":"G\u00f3mez Rueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Taus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"\u00c1lvarez \u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyes","family":"Bernab\u00e9-Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Chara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"L\u00f3pez-Brea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Vil\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria \u00c1ngeles","family":"Sala Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabel","family":"del Barrio D\u00edaz Aldagal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Esteban Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"L\u00f3pez Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"\u00c1lvarez Cabellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Dom\u00e9nech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Falagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Moreno Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Delgado Ure\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Isla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Bellido Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"F\u00edrvida P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3scar","family":"Juan-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartomeu","family":"Massut\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xabier","family":"Mielgo-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Laura","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Catot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"D\u00f3mine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Esco\u00edn-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Garc\u00eda Naval\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Gil-Bazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delvys","family":"Rodr\u00edguez-Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Mar\u00eda","family":"Villatoro Rold\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Alonso-J\u00e1udenes Curbera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Le\u00f3n-Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airam","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Paredes Lario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel","family":"S\u00e1nchez-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5899-6125","authenticated-orcid":false,"given":"Pilar","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Spanish Lung Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"issue":"3","key":"3404_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3404_CR2","unstructured":"Estimates for cancer incidence and mortality in 2020, (Lung cancer incidence and mortality), in all countries. Available at https:\/\/ecis.jrc.ec.europa.eu\/. Accessed 25 Nov 2022."},{"key":"3404_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061738","author":"A Agbary","year":"2022","unstructured":"Agbary A, Shalata W, Addeo A, Charpidou A, Cuppens K, Brustugun OT, et al. Real-world journey of unresectable stage III NSCLC patients: current dilemmas for disease staging and treatment. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11061738.","journal-title":"J Clin Med"},{"issue":"1","key":"3404_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5306\/wjco.v8.i1.1","volume":"8","author":"SM Yoon","year":"2017","unstructured":"Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 2017;8(1):1\u201320.","journal-title":"World J Clin Oncol"},{"issue":"19","key":"3404_CR5","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/jnci\/djr325","volume":"103","author":"WJ Curran Jr","year":"2011","unstructured":"Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452\u201360.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"3404_CR6","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1200\/JCO.19.01162","volume":"38","author":"JD Bradley","year":"2020","unstructured":"Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE, et al. Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2020;38(7):706\u201314.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3404_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12885-020-06734-3","volume":"20","author":"RN Hansen","year":"2020","unstructured":"Hansen RN, Zhang Y, Seal B, Ryan K, Yong C, Darilay A, et al. Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis. BMC Cancer. 2020;20(1):276.","journal-title":"BMC Cancer"},{"issue":"20","key":"3404_CR8","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"3404_CR9","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342\u201350.","journal-title":"N Engl J Med"},{"issue":"12","key":"3404_CR10","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S1470-2045(19)30519-4","volume":"20","author":"R Hui","year":"2019","unstructured":"Hui R, \u00d6zg\u00fcro\u011flu M, Villegas A, Daniel D, Vicente D, Murakami S, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(12):1670\u201380.","journal-title":"Lancet Oncol"},{"key":"3404_CR11","unstructured":"European Agency Medicines: Imfizi: EPAR \u2013 Product information, 2018. Available at https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imfinzi."},{"issue":"12","key":"3404_CR12","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","volume":"32","author":"J Remon","year":"2021","unstructured":"Remon J, Soria JC, Peters S, ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol. 2021;32(12):1637\u201342.","journal-title":"Ann Oncol"},{"issue":"12","key":"3404_CR13","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.21.02528","volume":"40","author":"ME Daly","year":"2022","unstructured":"Daly ME, Singh N, Ismaila N, Antonoff MB, Arenberg DA, Bradley J, et al. Management of stage III non-small-cell lung cancer: ASCO Guideline. J Clin Oncol. 2022;40(12):1356\u201384.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3404_CR14","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jtho.2020.12.015","volume":"16","author":"C Faivre-Finn","year":"2021","unstructured":"Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, et al. Four-Year Survival With Durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC Trial. J Thorac Oncol. 2021;16(5):860\u20137.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"3404_CR15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jtho.2019.10.002","volume":"15","author":"JE Gray","year":"2020","unstructured":"Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC. J Thorac Oncol. 2020;15(2):288\u201393.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"3404_CR16","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC Trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40(12):1301\u201311.","journal-title":"J Clin Oncol"},{"issue":"152","key":"3404_CR17","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0024-2019","volume":"28","author":"RM Huber","year":"2019","unstructured":"Huber RM, De Ruysscher D, Hoffmann H, Reu S, Tufman A. Interdisciplinary multimodality management of stage III nonsmall cell lung cancer. Eur Respir Rev. 2019;28(152): 190024.","journal-title":"Eur Respir Rev"},{"issue":"3","key":"3404_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12032-019-1249-1","volume":"36","author":"KJ Ryan","year":"2019","unstructured":"Ryan KJ, Skinner KE, Fernandes AW, Punekar RS, Pavilack M, Walker MS, et al. Real-world outcomes in patients with unresected stage III non-small cell lung cancer. Med Oncol. 2019;36(3):24.","journal-title":"Med Oncol"},{"issue":"10","key":"3404_CR19","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jtho.2021.05.003","volume":"16","author":"AR Jazieh","year":"2021","unstructured":"Jazieh AR, Onal HC, Tan DSW, Soo RA, Prabhash K, Kumar A, et al. Real-World treatment patterns and clinical outcomes in patients with stage III NSCLC: results of KINDLE, a Multicountry Observational Study. J Thorac Oncol. 2021;16(10):1733\u201344.","journal-title":"J Thorac Oncol"},{"issue":"22","key":"3404_CR20","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1200\/JCO.18.02118","volume":"37","author":"A Passaro","year":"2019","unstructured":"Passaro A, Spitaleri G, Gyawali B, de Marinis F. Immunotherapy in non-small-cell lung cancer patients with performance status 2: clinical decision making with scant evidence. J Clin Oncol. 2019;37(22):1863\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3404_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","volume":"18","author":"N Girard","year":"2023","unstructured":"Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, et al. Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R Study. J Thorac Oncol. 2023;18(2):181\u201393.","journal-title":"J Thorac Oncol"},{"key":"3404_CR22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.lungcan.2020.10.006","volume":"150","author":"M Faehling","year":"2020","unstructured":"Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, et al. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): real-world data on survival and safety from the German expanded-access program (EAP). Lung Cancer. 2020;150:114\u201322.","journal-title":"Lung Cancer"},{"issue":"4","key":"3404_CR23","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s10637-021-01091-9","volume":"39","author":"J Taugner","year":"2021","unstructured":"Taugner J, K\u00e4smann L, Eze C, R\u00fchle A, Tufman A, Reinmuth N, et al. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients. Invest New Drugs. 2021;39(4):1189\u201396.","journal-title":"Invest New Drugs"},{"key":"3404_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.744956","volume":"11","author":"A Bruni","year":"2021","unstructured":"Bruni A, Scotti V, Borghetti P, Vagge S, Cozzi S, D\u2019Angelo E, et al. A real-world, multicenter, observational retrospective study of durvalumab after concomitant or sequential chemoradiation for unresectable stage III non-small cell lung cancer. Front Oncol. 2021;11: 744956.","journal-title":"Front Oncol"},{"issue":"2","key":"3404_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/1759-7714.13764","volume":"12","author":"T Abe","year":"2021","unstructured":"Abe T, Saito S, Iino M, Aoshika T, Ryuno Y, Ohta T, et al. Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone. Thorac Cancer. 2021;12(2):245\u201350.","journal-title":"Thorac Cancer"},{"issue":"22","key":"3404_CR26","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1111\/1759-7714.14667","volume":"13","author":"Y Huang","year":"2022","unstructured":"Huang Y, Zhao JJ, Soon YY, Wong A, Aminkeng F, Ang Y, et al. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer. Thorac Cancer. 2022;13(22):3152\u201361.","journal-title":"Thorac Cancer"},{"issue":"3","key":"3404_CR27","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/cancers14030614","volume":"14","author":"K Sankar","year":"2022","unstructured":"Sankar K, Bryant AK, Strohbehn GW, Zhao L, Elliott D, Moghanaki D, et al. Real world outcomes versus clinical trial results of durvalumab maintenance in veterans with stage III non-small cell lung cancer. Cancers (Basel). 2022;14(3):614.","journal-title":"Cancers (Basel)"},{"key":"3404_CR28","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","volume":"28","author":"PE Postmus","year":"2017","unstructured":"Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv1\u201321.","journal-title":"Ann Oncol"},{"key":"3404_CR29","doi-asserted-by":"publisher","first-page":"viii488","DOI":"10.1093\/annonc\/mdy291","volume":"29","author":"C Faivre-Finn","year":"2018","unstructured":"Faivre-Finn C, Spigel DR, Senan S, Langer CJ, Raben D, Perez B, et al. Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC. Ann Oncol. 2018;29:viii488.","journal-title":"Ann Oncol"},{"issue":"12","key":"3404_CR30","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","volume":"17","author":"MC Garassino","year":"2022","unstructured":"Garassino MC, Mazieres J, Reck M, Chouaid C, Bischoff H, Reinmuth N, et al. Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: the phase 2 PACIFIC-6 trial. J Thorac Oncol. 2022;17(12):1415\u201327.","journal-title":"J Thorac Oncol"},{"key":"3404_CR31","doi-asserted-by":"publisher","first-page":"ix13","DOI":"10.1093\/annonc\/mdz438.021","volume":"30","author":"YL Wu","year":"2019","unstructured":"Wu YL, Wang L, Sendur MAN, Kim Y-C, Zhu Z, Chenget Y, et al. PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC. Ann Oncol. 2019;30:ix13\u2013114.","journal-title":"Ann Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03404-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03404-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03404-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T01:13:07Z","timestamp":1718327587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03404-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["3404"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03404-9","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,21]]},"assertion":[{"value":"8 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AGR has received speaker and consultant honoraria from AstraZeneca, Amgen and Takeda, and travel support from AstraZeneca, Takeda and MSD; AT has received personal fees and non-financial support from Pfizer, Roche, BMS, MSD, and AstraZeneca; RAA has received consultant and speaker honoraria from Boehringer, Novartis, Pharmamar and Roche, conference registration support from MSD Oncology, and has participated as PI coordinator in projects sponsored by Boehringer, Cebiotex, Janssen Oncology, Novartis, Rain Therapeutics and Roche; RBC has received speaker and\/or consultant honoraria from Pfizer, Janssen, Sanofi, AstraZeneca, Bristol Myers, Roche, Takeda and Jannsen, and research funding from Roche; LV has received consultant honorarium from Boehringer Ingelheim, AstraZeneca and Sanofi and speaker honoraria from AstraZeneca, Sanofi, MSD, Pfizer and Roche. MASG has received speaker and lecturer honoraria from Takeda and Roche, and travel\/meeting attendance support from Roche and PharmaMar; MD has received grants from Roche and travel\/meeting attendance support from Lilly; SF has received speaker honorarium from Pfizer and Sanofi, and travel support from AstraZeneca and MSD; CA has received consultant honorarium from AstraZeneca, BMS, MSD and Novartis, research funding from MSD, Mirati and AstraZeneca, and travel support from Roche, Novartis, Takeda and Pierre Fabre; AB has received speaker and consultant honoraria from BMS, Roche, MSD, Sanofi and Takeda, and travel support from MSD, Roche and BMS; DI has received speaker\/consultant honoraria from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Hoffmann-La Roche, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, Sanofi and Takeda\u200b, has participated in clinical trials sponsored by Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Hoffmann-La Roche, GSK, Janssen, Lilly, Merck, Mirati Therapeutics, MSD, Novartis, Pfizer and Sanofi, \u200band has received research grants from AstraZeneca, BMS, Hoffmann-La Roche and GSK; LBH has received speaker honorarium from Roche, BMS and AstraZeneca, consultant honorarium from Boehringer and Sanofi, and meeting attendance support from MSD, Novartis, Sanofi and AstraZeneca; JLFP has received consultant and speaker honoraria from AstraZeneca; BM has received personal fees from Roche, BMS, MSD, Boehringer Ingelheim and Pfizer; XMR has received speaker and\/or consultant honoraria from Novartis, Roche, Pfizer, Astra Zeneca and MSD, grants from BMS, travel\/meeting attendance support from Roche, Lilly and MSD, and declares his membership of the boards of the Spanish Group for Transversal Oncology and Research in Orphan and Infrequent Tumors (GETTHI) and the Spanish Group for Cancer Immuno-Biotherapy (GETICA); MD has received consultant and\/or speaker honoraria from AstraZeneca, Boehringer Ingelheim, Janssen Cilag, BMS MSD, Pfizer, Roche, Sanofi and Takeda; IGB has received consultant and\/or speaker honoraria from MSD Oncology, Lilly, AstraZeneca and BMS\/Celgene, Roche and Amgen, and travel support from MSD Oncology, Lilly and Daiichi Sankyo; DR-A has received consultant and speaker honoraria from Roche\/Genentech, AstraZeneca, BMS, Boehringer Ingelheim, MSD, Merck Serono, Eli Lilly, Gilead, Sanofi, Regeneron, Incyte, Pfizer, Takeda and Novartis, and travel support from Roche, BMS, MSD, Sanofi, Regeneron and Novartis; GAJC has received speaker\/consultant honoraria from AstraZeneca and Roche; LLM has received consultant\/speaker honoraria from AstraZeneca; JMST has received speaker\/consultant honoraria from AstraZeneca; PG has received consultant honorarium from Abbvie, Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, GlaxoSmithKline, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi and Takeda, and direct funding from Medscape and Touch Medical. All other authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study followed the Helsinki Declaration, Good Clinical Practices and the Spanish Organic Law 3\/2018 of 5 December on the Protection of Personal Data and digital rights guarantee. The study was approved by the Ethics Committee of Hospital Puerta de Hierro de Majadahonda (Madrid). Written informed consent was obtained from all enrolled patients. Patient medical information obtained for this study was confidential and was only disclosed to the researchers and third parties involved, as detailed in the informed consent form signed by the patients. Confidentiality standards were maintained by assigning each patient a unique subject identification number.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval (Research involving human participants and\/or animals) and Informed consent"}}]}}